Literature DB >> 16284974

Protective mechanisms of head and neck squamous cell carcinomas from immune assault.

M Rita I Young1.   

Abstract

Head and neck squamous cell carcinoma (HNSCC) is an aggressive malignancy that is the sixth most common neoplasm in the world. Despite advances in treatments involving surgery, radiation, and chemotherapy, the 5-year survival has remained at less than 50% for the past 30 years, primarily because of local recurrences. Thus, the possibility of immunotherapeutic approaches for patients with HNSCC has gained interest. Unfortunately, patients with HNSCC have profound immune defects that are associated with increased recurrence. This review aims to provide an overview of both the defensive and immune subversive mechanisms by which patients with HNSCC can protect themselves from immune antitumor assault. Copyright 2005 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2006        PMID: 16284974     DOI: 10.1002/hed.20331

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  27 in total

1.  Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma.

Authors:  Caroline J Voskens; Duane Sewell; Ronna Hertzano; Jennifer DeSanto; Sandra Rollins; Myounghee Lee; Rodney Taylor; Jeffrey Wolf; Mohan Suntharalingam; Brian Gastman; John C Papadimitriou; Changwan Lu; Ming Tan; Robert Morales; Kevin Cullen; Esteban Celis; Dean Mann; Scott E Strome
Journal:  Head Neck       Date:  2012-01-27       Impact factor: 3.147

2.  Premalignant Oral Lesion Cells Elicit Increased Cytokine Production and Activation of T-cells.

Authors:  Sara D Johnson; Corinne Levingston; M Rita I Young
Journal:  Anticancer Res       Date:  2016-07       Impact factor: 2.480

3.  Isopentenyl pyrophosphate-activated CD56+ {gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma.

Authors:  Alan A Z Alexander; Amudhan Maniar; Jean-Saville Cummings; Andrew M Hebbeler; Dan H Schulze; Brian R Gastman; C David Pauza; Scott E Strome; Andrei I Chapoval
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

4.  Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen.

Authors:  Neil L Berinstein; Gregory T Wolf; Paul H Naylor; Lorraine Baltzer; James E Egan; Harvey J Brandwein; Theresa L Whiteside; Lynn C Goldstein; Adel El-Naggar; Cecile Badoual; Wolf-Herve Fridman; J Michael White; John W Hadden
Journal:  Cancer Immunol Immunother       Date:  2011-11-06       Impact factor: 6.968

Review 5.  Checkpoint immunotherapy in head and neck cancers.

Authors:  Paul Zolkind; Ravindra Uppaluri
Journal:  Cancer Metastasis Rev       Date:  2017-09       Impact factor: 9.264

6.  A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma.

Authors:  Theresa L Whiteside; Lisa H Butterfield; Paul H Naylor; James E Egan; John W Hadden; Lorraine Baltzer; Gregory T Wolf; Neil L Berinstein
Journal:  Cancer Immunol Immunother       Date:  2011-11-23       Impact factor: 6.968

7.  Distribution of dendritic cell subtypes in primary oral squamous cell carcinoma is inconsistent with a functional response.

Authors:  Rebekah K O'Donnell; Rosemarie Mick; Michael Feldman; Satoshi Hino; Yan Wang; Marcia S Brose; Ruth J Muschel
Journal:  Cancer Lett       Date:  2007-06-18       Impact factor: 8.679

8.  Tumor-derived microvesicles in sera of patients with head and neck cancer and their role in tumor progression.

Authors:  Christoph Bergmann; Laura Strauss; Eva Wieckowski; Malgorzata Czystowska; Andreas Albers; Yun Wang; Reinhard Zeidler; Stephan Lang; Theresa L Whiteside
Journal:  Head Neck       Date:  2009-03       Impact factor: 3.147

Review 9.  Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers.

Authors:  Ravindra Uppaluri; Gavin P Dunn; James S Lewis
Journal:  Cancer Immun       Date:  2008-12-04

10.  Immunotherapy of head and neck cancer: current and future considerations.

Authors:  Alexander D Rapidis; Gregory T Wolf
Journal:  J Oncol       Date:  2009-08-09       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.